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The antirecombinant interleukin 2 (rec-IL-2) monoclonal 
antibody (moAb) 15.2 cross-reacts with a skin antigen lo-
cated at the cell surface of human keratinocytes within the 
granular layer [2]. This study extends the analysis of this 
IL-2-like material to its reactivity with eight antibodies 
raised against natural IL-2, rec-IL-2 or IL-2 peptides. Four 
among them were found to react with the granular epidermal 
layer as well as with a simian virus 40 (SV40) transformed 
human keratinocyte cell line. Each of these four antibodies 
gave similar labeling patterns, although with different inten-
sities, and competitively inhibited each other. Analysis at the 
messenger RNA level in epidermal cells and SVK 14 also 
indicated that this material is very likely different from IL-2. 
From the knowledge, for some of these antibodies, of the 
W e have recently shown that 15.2, a monoclo-nal antibody (moAb) raised against unglyco-sylated human recombinant interleukin 2 (rec-IL-2) [1] reacted with a human skin epi-tope located at the cell surface ofkeratinocytes 
within the granular layer of human epidermis [2]. thus providing a 
useful probe for the study of human epidermal cell differentiation. 
Because 17.2, a second anti-rec-IL-2 moAb, did not react under 
similar conditions, it was concluded that 15.2 staining reflected a 
cross-reactivity often encountered with moAbs. In an attempt to 
pinpoint the molecular nature of the antigen recognized by 15.2, as 
well as its relation to IL-2, however, we have extended the immu-
nochemical characterization of this antigen to the analysis of eight 
antibodies (including 15.2) reacting with different parts of the IL-2 
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amino-acid regions they recognize on the IL-2 molecule, it is 
inferred that the skin antigen shares with IL-2 at least two 
overlapping epitopes located in the 33 - 54 amino-acid re-
gion of IL-2, a region that has been shown to be involved in 
the binding of IL-2 to the IL-2-receptor (IL-2-R) 55 kD 
chain. Indeed, a purified recombinant soluble species of this 
IL-2-R is shown in this study to bind specifically to the 
IL-2-like skin material. As far as IL-2-R bearing cells are 
found in normal epidermis (Langerhans cells) and as impor-
tant infiltrates of IL-2-R positive T lymphocytes are often 
encountered in cutaneous diseases, a potential role for this 
IL-2-1ike material in skin immunophysiopathology is sug-
gested.] IrlVest DermatoI93:78 - 82, 1989 
molecule. A simian virus 40 (SV40) transformed human keratino-
cyte ce ll line (SVK14) [3] was also included in the study. In addition, 
we looked for the production ofIL-2 - messenger RN A (mRNA) by 
human epidermal cells and SVK14 cells. Finally, a potential binding 
by the IL-2-like skin material of a soluble form of the human IL-2-
receptor (IL-2-R) alpha chain was investigated. 
MATERIALS AND METHODS 
Skin Specimens Cutaneous sections were prepared from normal 
human skin biopsies that were snap frozen in liquid nitrogen, main-
tained at -80·C. and cut into 4-,Um sections using a cryostat. They 
were mounted on glass slides and kept frozen until use. 
Epidermal Cell Suspensions Blister roofs were obtained from 
normal human epidermis according to the suction blister method 
described by Kiistala [4] and epidermal cell suspensions prepared 
essentially as described by Liu et al [5]. Blister roofs were cut in small 
pieces and incubated for 1 hat 37·C in phosphate-buffered saline 
(PBS) containing EDTA (0.02%) and trypsin (0.05%){Cat. no. 
0152-13; Difco, Detroit, MI) . After detachment of epidermis from 
dermis with tweezers, both epidermal and dermal parts were 
minced between two scalpel blades. The epidermal cell suspensions 
thus obtained were washed extensively with Dulbecco's minimal 
Eagle's medium (Gibco, Glasgow, Scotland) containing 10% fetal 
calf serum (Flow Laboratories, Puteaux, France), rinsed in PBS and 
used for RNA extraction. 
SVK14 Cell Suspensions The SVK14 cell line is a human kera-
tinocyte cell line established after SV40 transformation and was 
kindly given to us by Dr B. Lane (Imperial Cancer Research Fund, 
London) [3]. This adherent cell line was routinely cultured in RPMI 
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Table I. Characteristics of the Antihuman IL-2 Antibodies 
Anti-IL-2 Antibody 
IHII-IA5 
9Bll-1E5 
R135 (p8 - 27) 
R221 (p38-54) 
Fl-441-5D2 
Fl-307-4B5 
Fl-307-2Fl1 
15.2 
• J.R. Robb. unpublished. 
IL-2 Segment Recognized 
1- 8 (N-acetylgal) 
33 - 54 
8- 27 
38 - 54 
unknown 
unknown 
unknown 
unknown 
1640 medium (Gibco) containing 10% fetal calf serum. For the 
preparation of cell suspensions, cells were washed and incubated 
with trypsin (0.05%) and EDTA (0.02%) for 10 min at 37°C, 
detached, rinsed with culture medium and PBS. They were either 
extracted for RNA isolation, spread on glass slides, air dried, fixed 
with acetone, and stored frozen until used for immunofluorescence 
studies, or resuspended in PBS conta ining 0.5% bovine serum albu-
min (BSA) for binding experiments. 
Antibodies, Interleukin 2, and Soluble Intedeukin 2 Recep-
tor The 15.2 moAb (IgG2) was isolated from a cell fusion using a 
BALB/c mouse immunized with recombinant IL-2 produced in 
Escherichia coli [1]. The seven other anti-IL2 antibodies, which are 
either mouse moAb or rabbit polyelonal affinity-purified IgG frac-
tions, obtained either against natural Jurkat IL-2 or synthetic pep-
tides of human IL-2 [6-8], were kindly given to us by J.R. Robb 
(Dupont, Glenolden, PA) and are listed in Table I. 
The rec-IL-2 was produced in E.co/i and was kindly given to us by 
D. Lando (Roussel-Uelaf, Romainville, France). The soluble IL-2-
R was a purified, recombinant molecule secreted by rodent cells 
transfected with an IL-2-R alpha chain (55kD) cDNA in which the 
coding sequences for the cytoplasmic and transmembrane domains 
had been excised. It was a generous gift from S. IP (T Cell Sciences, 
Cambridge, MA). 
The 33B3.1 moAb (IgGJ is a rat antihuman IL-2-R alpha chain 
that interferes with IL-2 binding [9,10], whereas 7G7/B6 moAb 
(IgG2), a mouse anti-IL-2-R alpha chain that does not compete with 
IL-2 binding [11] was a kind gift from D.L. Nelson (N.C.I., Be-
thesda, MD). 
Indirect Immunofluorescence on Cutaneous Sections and 
SVK14 Cell Suspensions Samples (cell smears or skin sections) 
were immersed for 10 min in acetone and washed with PBS. The 
anti-IL-2 antibodies were then applied at a concentration of 4 Jig/ml 
in PBS for 30 min at room temperarure. Biotin-conjugated goat 
anti mouse or goat antirabbit IgG fractions (Immunotech, Marseille, 
France) were then applied (1 : 100 in PBS) for 30 min, washed, and 
fluorescein-conjugated streptavidin (Immunotech, 1: 100 in PBS) 
was added for 30 min. After washing in PBS during 1 h, the samples 
were mounted using buffered glycerin and examined at X400 mag-
nification using a Zeiss UV microscope. In some experiments (Figs 
2 and 3), nuclei were counterlabeled with propidium iodine. 
In experiments using the soluble IL-2-R, acetone.-fixed samples 
were immersed for 30 min at room temperature WIth the soluble 
IL-2-R. The 7G7/B6 moAb was then applied at 5 Jig/ml for 30 min 
and, after washing, a goat antimouse antibody conjugated with fluo-
rescein (1 : 100 in PBS, Eurobio, Paris, France) was added ~or 30 
min. In competition studies, rec-IL-2 was used at a concentration of 
660 nM and the 33B3.1 moAb, the R221-anti-p38-54, R135-anti-
p8-27, or control rabbit IgG were used at 20 Jig/ml. 
Northern Blot Analysis Total cellular RNA was isolated from 
intact cells (3 X 107) by using a guanidine isothiocyanate lysis pro-
cedure [12J followed by centrifugation on cesium chloride gradient. 
Equal amounts of RNA (15 or 30 Jig whole cell RNA) were dena-
tured for 15 min at 60°C in electrophoresis buffer (20 mM morpho-
molinopropane sulfonic ac id,S mM sodium acetate, 1 mM EDT A, 
6% formaldehyde) containing 50% formamide, quickly chilled on 
IgG Species/Subclass 
IgG2a mouse moAb 
IgG 1 mouse moAb 
IgG rabbit mix 
IgG rabbit mix 
IgG mouse moAb 
IgG mouse moAb 
IgG mouse moAb 
IgG2a mouse moAb 
Reference 
(6) 
(7) 
(7) 
(8) 
(I) 
ice and size-fractionated by electrophoresis through a 1 % agarose 
gel containing 6% formaldehyde. The blotting was performed on 
Genescreen Plus filter (New England Nuclear, Boston, MA) ac-
cording to the supplier and hybridized for 20 h at 42°C with heat-
denatured 32P-nick translated IL-2-cDNA probe (pAT153-hIL2, a 
kind gift from W. Fiers [13]. The hybridization was conducted in 
40% formamide, 1 % sodium dodecyl sulfate, 900 mM NaCI, SO 
mM phosphate buffer, pH 6.5, 2 mM EDTA, 0.08% (w Iv) each of 
BSA, Ficoll and polyvinylpirrolidone, 4% dextran sulfate, 200 
Jig/ml denatured herring sperm DNA. The filter was washed twice 
for 10 min at room temperature, twice for 10 min at 60°C in the 
presence of 2xSSC (1 xSSC = 150 mM NaCI and 15 mM trisodium 
citrate) and 0.1 % sodium dodecyl sulfate. They were exposed for 1 
to 3 d at -80°C on Kodak x-o mat X ray film using intensifying 
screens. 
Radiolabeling of the Soluble Interleukin 2 Receptor and 
Binding to SVK14 Cells The soluble IL-2-R was labeled with 
125-iodine (Amersham, Les Ulis, France) using the two phrase 
iodination technique described by Tejedor and Ballesta [14). It was 
labeled at a specific activity of 1200 cpm/femtomole. SVK14 cell 
suspensions prepared in PBS - O.5% BSA were sampled in round-
bottomed multiwell plates (Nunc, Roskilde, Denmark) at a concen-
tration of 105 cells per well to which increasing concentrations of 
radiolabeled IL-2-R were added. Nonspecific binding was obtained 
by including a 50-fold excess of unlabeled soluble IL-2-R in the 
assay. Incubation was carried out at 37"C for 45 min. Cells were 
collected and cell bound and unbound radioactive fractions were 
separated on a layer of dibutylphthalate-paraHin oil and counted as 
described [9]. 
RESULTS 
Antibodies Staining of Cutaneous Sections and SVK14 
Cells Among the eight antibodies studied at the same concentra-
tion (4 Jig/ml), four of them (15 .2, 9B l1-1E5, R221-anti-p38 - 54, 
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Figure 1. Photomicrograph of antibody labeling patcerns on human epi-
dermis (rop panel) and on SVK 14 cells (bollom panel) . Antibodies tested were 
15.2 (A) , 9Bll-IE5 (B) , R221-anri-p38 - 54 (e), and Fl-441-5D2 (D) . All 
showed an intercellular staining pattern restricted to the granular layer of the 
epidermis (rop pa'leI) and a cell surface patcern on SVK14 cells (borrom panel) . 
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Figure 2. Photomicrograph of human epidermis stained with antibody 
9B l1 -1E5. A typical granular layer pattern is seen (A) , which is abolished by 
preincubation with antibody R221-anti-p38 - 54 (B) . Epidermal cell nuclei 
are counterstained with propidium iodine. 
and FI-441-5D2) gave a specific labeling on cutaneous sections (Fig 
lA) . In each case, the labeling was associated with the cell surface of 
keratinocytes or intercellular spaces, or both, and restricted to the 
granular layer of the epidermis. The 15.2 moAb gave the strongest 
signal. For three of them (9Bll-1E5, R221, and FI-441-5D2) the 
labeling was weak but detectable using the conventional indirect 
immunofluorescence technique (not shown). It was more clearly 
evidenced with the streptavidin - biotin amplifying method (Fig 
lA). In contrast, antibodies IH II-lAS, R135-anti-p8 - 27, Fl-307-
B5, and FI-307-2Fl1 were negative whatever the labeling method 
used. When the anti-IL-2 antibodies were run on the SVK14 cell 
line, 100% of the cells were labeled only with the same four anti-
bodies reactive on epidermis (Fig 1B). 
Antibodies Competition Studies To analyze whether the posi-
tive moAb reacted with separate or overlapping epitopes on epider-
mal cells, competitive binding studies were set up (Fig 2). In these 
experiments, the cutaneous sections were first preincubated with 
R221 -anti-p38 - 54 (rabbit IgG) before applying the 9B11-1E5 or 
the 15.2 mice moAb and revealing with an antimouse antiserum and 
the streptavidin - biotin amplifying complex. Preincubation with 
R221 completely abolished 9B11-1E5 or 15.2 stajning, whereas 
preincubation with R 135-anti-p8 - 27 (rabbit IgG) had no effect. 
Similarresults were obtained on the SVK14 cell line (not shown). In 
other experiments (not shown), cutaneous sections where preincu-
bated with human rec-IL-2 before labeling with the antibodies. As 
already shown for 15.2 [2], this preincubation step abrogated the 
labeling with 9B11-1E5, R221-anti-p38 - 54, and F1-441-5D2. 
Labeling of Cutaneous Sections and SVK14 Cells With a Sol-
uble Interleukin 2 Receptor Alpha Chain As shown in Figure 
3A, preincubation of cutaneous sections or SVK14 cells with the 
soluble IL-2-R (concentration 600 nM) followed by incubation 
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Figure 3. Photomicrograph of human epidermis stained with soluble IL-2-
R. Granular layer eridermal staining (A) is abolished by preincubation with 
recombinant lL-2 (B) and by monoclonal antibody 33B3.1 (C) . Epidermal 
cell nuclei are counterstained with propidium iodine. 
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with the 7G7/B6 moAb, a mouse antihuman IL-2-R alpha chain 
that does not interfere with IL-2 binding to the receptor [11], re-
sulted in a specific labeling of the cutaneous sections with a pattern 
very similar to those obtained with the four anti-IL-2 antibodies, 
i.e., located at the cell surface of keratinocytes and restricted to the 
granular layer. This labeling was not observed when the IL-2-R was 
first preincubated with rec-IL-2 (Fig 3B). Moreover, the rabbit anti-
IL-2 antibody R221-anti-p38 - 54 also blocked the soluble IL-2-R 
labeling, whereas the other rabbit anti-IL-2 antibody R135-anti-
p8 - 27 as well as control rabbit IgGs had no effect (not shown). 
Conversely, preincubation of the cutaneous sections with the solu-
ble IL-2-R completely abrogated the 15.2, 9B11-1E5, R221-anti-
p38 - 54, and F1-441-5D2Iabelings (not shown). When 33B3.1, a 
rat anti-IL-2-R alpha chain moAb that blocks IL-2 binding to the 
receptor [9,10] was used instead of or together with 7G7/B6, no 
labeling could be observed (Fig 3C). Additional control experi-
ments (not shown) omitting the soluble IL-2-R, 7G7/B6 or the 
second anti mouse antibody gave background staining. Staining 
with the soluble IL-2-R was also dose-dependent and a detectable 
staining of the granular layer could still be observed at a soluble 
IL-2-R concentration of 60 nM (data not shown). Similar observa-
tions were obtained with the SVK14 cell line (not shown). 
Binding of the 125-1 Labeled Soluble Interleukin 2 Receptor 
to SVK14 Cells To quantitate more precisely the binding of the 
soluble IL-2-R to human keratinocytes, a direct binding experiment 
of radiolabeled IL-2-R to SVK14 cell suspensions was carried out 
(Fig 4). A specific binding component was observed that, after Scat-
chard analysis, gave a maximal binding capacity of 8023 binding 
sites per cell and a dissociation constant (KJ) of 15.5 nM. 
Analysis ofInterleukin 2 Gene Expression in Human Epider-
D131 Cells and SVK14 Cells The IL-2 mRNA levels were exam-
ined by Northern-blot analysis of RNA prepared from epidermal 
cell suspensions and SVK14 cells. RNA from the Jurkat cell line 
isolated 10 h after stimulation with Phaseolus vulgaris phytohemag-
lutinin (PHA-P) (1%) and phorbol12-myristate 13-acetate (PMA) 
(100 J.lg/ml) and those from two alloreactive T cells clones 4AS and 
1B4 [15] purified 5 h after stimulation with PMA (20 J.lg/ml) and 
Ca++ ionophore (2 J.lM) were used as positive controls. As shown 
in Figure SA, when 15 J.lg of total RNA was blotted and after over-
night exposure, a strong IL-2-mRNA signal was obtained as a 
0.85 Kb band in the controls, whereas no signal could be detected 
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Figure 4. Graph depicting binding of 125-1-labeled soluble lL-2-R to 
SVK14 cells: cell bound radioactivity (ordinates) is expressed as a function of 
unbound fraction (abscissae) after substraction of nonspecific binding. 
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Figure 5. Northern blot analysis of IL-2-mRNA. A: Analysis of 15 J.Lg of 
total RNA from Jurkat line stimulated with PHA-P plus PMA (lane 1), 
SVK14 cell line (lane 2), and two alloreactive human T cell clones stimu-
lated with PMA plus Ca++ ionophore (lanes 3 and 4). Overnight exposure. 
B: Analysis of 15 J.Lg total RNA from Jurkat (PHA-P plus PMA) (lane 1), 15 
and 30 J.Lg RNA from human epidermal cell suspensions (lanes 2 and 3), and 
15 and 30 J.Lg RNA from the SVK14 line (lanes 4 and 5). Three days of 
exposure. 
with SVK 14 cells. In a second experiment (Fig 5B), 15 and 30,ug 
whole cell RNA from human epidermal cell suspensions and 
SVK14 cells were similarly analyzed as well as 15 f.1.g of total RNA 
from Jurkat as positive control. After a 3-d exposure, a strong IL-2-
mRNA signal was obtained in Jurkat cells and was absent on the 
keratinocyte cell line. Human epidermal cells were also negative at 
15 f.1.g total RNA, although a weak but definite signal could be 
detected when 30 f.1.g of RNA were applied. 
DISCUSSION 
This study extends an earlier report [2] describing a cross-reactive 
labeling of human granular layer keratinocytes by an anti-rec-IL-2 
moAb (15.2). It shows that among a series of eight antibodies di-
rected against different epitopes of the IL-2 molecule, four of them 
cross-reacted with an antigen located on the granular layer of 
human keratinocytes and also present on the SV 40-transformed 
keratinocytes cell line SVK14. As already reported for the 15.2 
moAb [2), staining of cutaneous sections was always located at the 
cell surface or the intercellular spaces, or both. As far as the staining 
was still present after trypsin treatment and washing of epidermal 
cells, at least part of the antigen recognized is likely associated with a 
cell surface compartment. Each of these four antibodies gave similar 
labeling patterns, although with different intensities, and 15.2 was 
the most reactive. The streptavidin - biotin amplyifying method 
was indeed required to reveal the binding of three of these antibod-
ies (9Bll-1E5, R221-anti-p38 - 54, and Fl-441-5D2), which only 
gave a weak staining by the indirect immunofluorescence tech-
nique. These differences might be related to differential affinities of 
the antibodies for the skin antigen. 
Among the eight antibodies used in this study, four of them have 
been characterized for the epitopes they recognize on the human 
IL-2 molecule. The moAb 1 H11-1A5 recognizes the N-terminal 
segment 1-8 and reacts best when a N-acetylgalactosamine is on 
Thr 3 [16]. The moAb R135-anti-p8-27 binds to an epitope in-
volving amino acids preceding residue 26. The moAb 9Bll-1E5 
binds at the N-terminal half of the 33 - 54 IL-2 segment, whereas 
R221-anti-p38 - S4 recognizes the C-terminal portion of the 33-
54 segment, the epitopes recognized by these two antibodies being 
distinct but overlapping [8] . It is precisely 9Bll-1ES and R221-
anti-p38 - 54 that were found to be reactive with keratinocytes, 
1Hll-1AS and R13S-anti-p8 -27 being unreactive. Moreover, 
9B11-1E5 and R221-anti-p38 - S4 also competed for binding to 
keratinocytes, and their labeling was abrogated in the presence of 
excess rec-IL-2. These results, therefore, suggest that the skin anti-
gen shares with human IL-2 at least the two epitopes defined by 
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9B11-1E5 and R221-anti-p38-S4 and that these epitopes are spa-
cially arranged (i.e., overlapping) in a way similar to what found on 
IL-2. More recent data using these antibodies indicated that IL-2 
binding to the SS kD alpha chain involved an IL-2 segment in the 
33-54 amino-acid region, whereas IL-2 binding to the newly de-
scribed 75 kD beta chain involved a site within its N-terminal re-
gion (residues 1-27) [17]. These findings, therefore, prompted us 
to analyze whether the skin antigen sharing with IL-2 two epitopes 
located in the 33 - S4 segment would be able to bind the SS kD 
;;1pha chain. As far as the naturally produced soluble form of the 
IL-2-R alpha chain has been shown to bind IL-2 as well as anti-alpha 
chain moAb with similar affinities as the memgrane IL-2-R alpha 
chain [18], a highly purified soluble IL-2-R recombinant molecule 
was used to test this hypothesis. Preincubation of cutaneous sections 
with soluble IL-2-R followed by application of 7G7/B6, an anti-
IL-2-R alpha chain that does not compete with IL-2 binding [11] 
indeed resulted in the labeling of the granular layer ofkeratinocytes 
in a way strickingly similar to those observed with anti-IL-2 anti-
bodies. Additional evidence that the soluble Il-2-R and anti-IL-2 
antibodies recognized a common structure on keratinocytes is as 
follows: 1) preincubation with an anti-IL-2 antibody reactive on 
skin (R221-anti-p38 -54) abolished the staining with the soluble 
~L-2-R, whereas the unreactive counterpart (R135-anti-p8 -27) or 
ur.elev~nt rabbit IgG were without effect and 2) preincubation of 
skin WIth the soluble IL-2-R blocked the staining obtained with the 
four antibodies reactive in our studies. The specificity of the staining 
with the soluble IL-2-R was further assessed by the fact that 1) it was 
not observed after preincubation of skin with rec-IL-2; 2) another 
a~ti-~L-2-R alpha chain, 33B3.1, which does compete with IL-2 
binding to the IL-2-R [9,10J, gave no labeling under comparable 
experimental conditions; and 3) 33B3.1 inhibited the labeling ob-
~ined with the association of soluble IL-2-R and 7G7/B6. Finally, a 
duect demonstration of the specific binding of radio labeled soluble 
IL-2-R to SVK14 cells could be obtained and showed that the solu-
ble IL-2-R bound to the skin antigen with an affinity (KJ = 
15.5 nM) comparable to that already reported for its binding to 
rec-IL-2 (KJ = 30 nM) [18]. Together these data strongly suggest 
that binding of the soluble IL-2-R to the skin antigen involves a 
region of the IL-2-R alpha chain committed in IL-2 binding. 
The lack of skin labeling with the other four anti-IL-2 antibodies 
(1H11-1A5, R13S-anti-p8 -27, FI-307-4B5, and Fl-307-2Fll) 
raises several interpretations; 1) The skin antigen might be IL-2 that 
is adsorbed at the cell surface and presented in such a way that only 
part of its epitopes are exposed. 2) It might be IL-2 chemically 
modified so that only part of the molecule retains its original antige-
nicity; in this respect, a difference in the N-glycosylation at Thr 3 
would be compatible with a lack of staining with the 1HI1-1AS 
moAb [16] . 3) It might be a molecule unrelated to IL-2 but sharing 
with it a common structural domain; in that case the partial struc-
tural homology might reflect or not an amino-acid sequence ho-
mology between IL-2 (33 - 54 region) and the skin antigen. Al-
though a clear answer to these various possibilities awaits 
biochemical characterization of the skin antigen, analysis at the 
messenger level was carried out to look for IL-2- mRNA in epider-
mal cells. Results show that, in contrast to control Jurkat cells or 
alloreactive human T cell clones that gave a very strong mRNA 
signal with the IL-2-cDNA probe, SVK14 keratinocytes that are 
100% and strongly labeled with the anti-IL-2 antibodies are nega-
tive even at 30 f.1.g total RNA with the IL-2-cDNA probe. These 
data, therefore, strongly suggest that the skin antigen detected by 
the anti-IL-2 antibodies is not IL-2 itself. This conclusion agrees 
with previous reports documenting either the absence ofIL-2 activ-
ity in supernatants of ef.idermal cell cultures as measured by induc-
tion ofCTL-L2 [19,20 ,or CT6 proliferation [21], or the absence of 
IL-2 - mRNA expression by the murine keratinocyte cell line PAM 
212 [22] . 
A weak IL-2 mRNA band was detected on human epidermal cells 
at high levels of RNA. Our interpretation is that it is related to the 
presence within the epidermal suspension of a minor cell population 
different from keratinocytes and able to produce IL-2 {Langerhans 
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cells, indeterminate dendritic cells, contaminating lymphocytes). 
Such cells are obviously not present in the SVK14 cell line, which 
was developed as a clone from a single SV40 transformed keratino-
cyte [3] . 
Together our data favor the hypothesis that granular keratino-
cytes from human epidermis express a cell-surface antigen different 
from IL-2 that shares with it a structural domain able to bind a set of 
four monoclonal antibodies and to bind the alpha chain of the IL-2-
R. Although the validity of this hypothesis needs to be confirmed by 
more quantitative binding data and biochemical identification of 
this IL-2-like material, it raises the attracting possibility that this 
antigen could participate in skin immunophysiology and pathology 
in various ways. Indeed, as far as Langerhans cells have been shown, 
at least in mice, to express the IL-2-R alpha chain [23], one could 
envisage a functional interaction between these cells and the kerati-
nocytes. A soluble IL-2-R alpha chain produced by Langerhans cells 
would be a potential mediator for this interaction. The reverse situa-
tion would be a soluble form of the skin antigen as mediator. Fi-
nally, as important infiltrates of IL-2-R alpha chain positive T lym-
phocytes (mainly of the helper phenotype) are encountered in 
several cutaneous diseases (cutaneous T lymphoma, eczema), simi-
lar functional interactions between these T lymphocytes and the 
IL-2-like skin antigen could be envisaged. 
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